title: Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease.
abstract: The use of anti-tumour necrosis factor (TNF) agents has expanded significantly over the past few years, particularly for rheumatological diseases and Crohn's disease. A number of associated opportunistic infections have been observed as a result of suppression of T cell-mediated immunity, the most frequent being tuberculosis. We report the first case of pulmonary actinomycosis in a patient receiving regular infusions of infliximab, an anti-TNF agent, for Crohn's disease.
authors.affiliation: Department of Medicine, University of British Columbia, Vancouver, Canada. richardcohen@shaw.ca
authors.forename: R D
authors.initials: RD
authors.lastname: Cohen
authors.forename: W R
authors.initials: WR
authors.lastname: Bowie
authors.forename: R
authors.initials: R
authors.lastname: Enns
authors.forename: J
authors.initials: J
authors.lastname: Flint
authors.forename: J M
authors.initials: JM
authors.lastname: Fitzgerald
mesh_terms: D000196:Actinomycosis / Q000139:chemically induced*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D000069285:Infliximab; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced*
chemical_list: D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab